FDA Funding In Cures Bill Complicated By Metrics, Appropriators
Executive Summary
But a Harvard researcher argues to improve drug development, basic research should receive more money because FDA review is not the problem.
You may also be interested in...
Unsure About ‘Breakthrough’-Worthiness? Talk To FDA First
An early, informal conversation between a sponsor and the review division about the supportive data could help reduce the number of ‘breakthrough therapy’ designation requests that are ultimately denied, FDA and sponsors said.
Congressional ‘Cures’ Debate Shifts To FDA Funding
House Democrats say FDA will need more money to be able to handle the responsibilities in the draft bill, while the agency worries reviews could slow without more resources.
The Evolution Of US FDA Advisory Committee Votes On COVID-19 Vaccines
From surprisingly contentious to surprisingly unanimous, VRBPAC's favorable votes have grown from 17 to 21 over the course of three meetings on coronavirus vaccines.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: